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Aim Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either persistent or paroxysmal atrial
fibrillation (AF). We compared outcomes in patients with persistent vs. paroxysmal AF receiving oral anticoagulation.
Methods
and results
Patients randomized in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antag-
onism for Preventionof Strokeand EmbolismTrial in Atrial Fibrillation (ROCKET-AF) trial (n ¼ 14 264)weregroupedby
baseline AF category: paroxysmal or persistent. Multivariable adjustment was performed to compare thrombo-embolic
events, bleeding, and death between groups, in high-risk subgroups, and across treatment assignment (rivaroxaban or
warfarin). Of 14 062 patients, 11 548 (82%) had persistent AFand 2514 (18%) had paroxysmal AF. Patients with persistent
AF were marginally older (73 vs. 72, P ¼ 0.03), less likely female (39 vs. 45%, P, 0.0001), and more likely to have pre-
viously used vitamin K antagonists (64 vs. 56%, P, 0.0001) compared with patients with paroxysmal AF. In patients ran-
domized to warfarin, time in therapeutic range was similar (58 vs. 57%, P ¼ 0.94). Patients with persistent AF had higher
adjusted rates of stroke or systemic embolism (2.18 vs. 1.73 events per 100-patient-years, P ¼ 0.048) and all-cause mor-
tality (4.78 vs. 3.52, P ¼ 0.006). Rates of major bleeding were similar (3.55 vs. 3.31, P ¼ 0.77). Rates of stroke or systemic
embolism in both types of AF did not differ by treatment assignment (rivaroxaban vs. warfarin, Pinteraction ¼ 0.6).
Conclusion In patients with AFatmoderate-to-high riskof stroke receiving anticoagulation, thosewith persistent AF havea higher risk
of thrombo-embolic events and worse survival compared with paroxysmal AF.
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Introduction
Atrial fibrillation (AF) is a progressive disorder, often transitioning
from intermittent to continuous arrhythmia. Patients experiencing
episodic AF, self-terminating within 7 days, are said to have
paroxysmal AF; patients whose arrhythmia persists beyond 7 days
(or requires intervention to terminate) are considered to have per-
sistent AF. Several prior studies have documented symptomatic,
physiologic, and anatomic differences between patients with parox-
ysmal and persistent AF.1,2 This categorization of AF can also have
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important implications for approaches to maintain sinus rhythm.3 All
the patients with AF are at an increased risk of thrombo-embolism
(stroke or systemic embolism) compared with patients without AF,
and anticoagulation therapies are recommended in all patients with
AF who are at moderate-to-high risk of stroke.4,5 The distinction
between paroxysmal and persistent AF has not been used to guide
choice of stroke prophylaxis, as it remains unclear whether patients
with persistent AF are at higher risk compared with those with par-
oxysmal AF, particularly in patients with additional risk factors for
stroke.6 The objectives of the current analysis were to (i) measure
the differences, if any, in outcomes between anticoagulated patients
with persistent vs. paroxysmal AF who had additional risk factors for
stroke, and (ii) determine whether there was a difference in treat-
ment effect between rivaroxaban and warfarin in these groups.
Methods
This was a post hoc analysis of the Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K Antagonism for Preven-
tion of Stroke and Embolism (ROCKET-AF) trial. The design of the
ROCKET-AF study has been previously described (NCT00403767).7
In brief, ROCKET-AF was a prospective, randomized, double-blind,
placebo-controlled trial of fixed-dose rivaroxaban vs. adjusted-dosewar-
farin for the prevention of stroke or systemic embolism in patients with
non-valvular AF at a high risk of stroke. All the patients had to have elec-
trocardiographic evidence of AF within 30 days prior to randomization;
additionally, they had to have medical evidence of AF within the previous
year. Patients were categorized by the enrolling physician at baseline as
having either paroxysmal (lasting ≤7 days at any time) or persistent AF
(.7 days at a time); no other AF types were provided as choices. Patients
were subsequently assessed in clinic at least as frequently as every 4
weeks, and this included ascertainment of interval events.
The present study included all patients randomized in the
ROCKET-AF trial [intention-to-treat (ITT)]. Patients were grouped
according to the type AF at baseline enrolment (paroxysmal or per-
sistent) according to pre-specified diagnostic criteria and prior to
any analysis of the data. Patients with new-onset AF at baseline [1.4%
(n ¼ 202)] were excluded from this analysis. Baseline characteristics
and outcomes were compared between these groups (paroxysmal or
persistent). Outcomes were further stratified by subgroups of interest:
CHADS2 scores (2 vs. ≥3),8 duration of AF diagnosis (≤6 vs. .6
months), baseline electrocardiogram (ECG) (AF or atrial flutter vs.
other), presence of congestive heart failure (CHF), history of prior
stroke, and presence of significant renal dysfunction (defined as creatin-
ine clearance ,60 mL/min).9
Outcomes
Pre-specified outcomes in the ROCKET-AF trial have been described
previously.7,10 The presentanalysis comparedoutcomesbetweenparox-
ysmal or persistent AF, as defined at baseline. The primary efficacy end-
point for this analysiswas stroke (ischaemicor haemorrhagic)or systemic
embolism in the ITT population. Additional secondary outcomes
included stroke only, transient ischaemic attack (TIA) only, stroke or
TIA, all-cause mortality, and a composite of stroke, systemic embolism,
or death. As in other ROCKET-AF analyses, 93 patients were excluded
from the efficacy analyses due to violations of Good Clinical Practice at
the enrolling centre. The safety outcome of major bleeding was assessed,
and limited to the safety population (patients in the ITT population who
received at least one dose of study medication).
Statistical methods
Baseline characteristics are presented as per cent (count) for categorical
variables and as medians (25th, 75th percentiles) for continuous vari-
ables. Groups were compared using Wilcoxon rank-sum tests for con-
tinuous variables and Pearson chi-square tests for categorical variables.
For each of the end-points, event rates (events per 100 patient-years
and total events) were generated. Comparisons were performed using
Coxproportional hazards models. All models were adjusted for variables
found to be predictive of efficacy and safety end-points in the full
ROCKET-AF cohort.9,11 Efficacy end-point models were adjusted for
the following (at baseline): age, sex, body mass index (BMI), region, dia-
betes, prior stroke/TIA, vascular disease [myocardial infarction (MI), per-
ipheral artery disease (PAD), carotid occlusive disease], CHF,
hypertension, chronic obstructive pulmonary disease, diastolic blood
pressure (BP), creatinine clearance (calculated using the Cockcroft–
Gault equation),12 heart rate, and abstinence from alcohol. Safety end-
point models were adjusted for the following (at baseline): age; sex;
region; prior stroke/TIA; anaemia; prior gastrointestinal bleed; chronic
obstructive pulmonary disease; diastolic BP; creatinine clearance (Cock-
croft–Gault equation);12 platelets; albumin; and prior aspirin, vitamin K
antagonist, or thienopyridine use. Missingness was low overall –,0.1%
for any efficacy model covariate, and,3% for any safety model covariate.
Where missing, covariates were imputed using the median for continu-
ous variables and the mode for categorical variables.13 The above efficacy
and safety models also contained randomized treatment (rivaroxaban or
warfarin). Hazard ratios (HRs) [with 95% confidence intervals (CI)] and
P-values are presented.
In analyses of subgroups, a similar approach was used: event rates
(events per 100 patient-years and total events) were generated for
each combination of AF type (paroxysmal or persistent) and subgroup.
The same Cox proportional hazards models were used, with the addition
of a term for the subgroup (where not already in the model) and for the
interaction between subgroup and AF type. Hazard ratios (with 95% CIs)
for paroxysmal vs. persistent AF within each subgroup, along with the
interaction P-value, were calculated.
To assess the difference in treatment effect, if any, between rivaroxa-
ban and warfarin across AF type, the above models were used with the
addition of a term for the interaction between treatment assignment
and AF type. Hazard ratios (with 95% CIs) for rivaroxaban vs. warfarin
within each AF type, along with the interaction P-value, are presented.
All the patients provided written, informed consent and all statistical
analyses were performed by the Duke Clinical Research Institute
(Durham, NC) using the SAS software (version 9.2, SAS Institute, Cary,
NC, USA).
Results
Patient characteristics
Characteristics of the patients, stratified by AF type at baseline,
are shown in Table 1. Treatment assignment was balanced across
AF types. Compared with patients with persistent AF at baseline,
those with paroxysmal AF were slightly younger (median age 72 vs.
73 years, P ¼ 0.03), more likely female (45 vs. 39%, P, 0.0001),
with lower baseline heart rate (median 72 vs. 76 beats/min,
P, 0.0001), and lower rates of diabetes (37 vs. 41%, P ¼ 0.0003)
and CHF (56 vs. 64%, P, 0.0001). However, mean CHADS2 (3.5
for each, P ¼ 0.3) and CHA2DS2-VASc (4.9, P ¼ 0.07) scores were
both balanced between patients with paroxysmal and persistent
AF, and rates of prior thrombo-embolic evens were higher in patients
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Table 1 Patient characteristics
Paroxysmal AF (n 5 2514) Persistent AF (n5 11 548) P-value
Randomized to rivaroxaban, % (n) 50% (1245) 50% (5786) 0.60
Age 72 (65, 78) 73 (65, 78) 0.033
Female, % (n) 45% (1121) 39% (4459) ,0.0001
CHADS2 score, mean (SD) 3.5 (0.9) 3.5 (0.9) 0.32
CHADS2 score, % (n)
1 0 ,1% (3)
2 13% (334) 13% (1510)
3 44% (1110) 43% (4997)
4 28% (716) 29% (3319)
5 12% (304) 13% (1489)
6 2% (50) 2% (230)
CHA2DS2-VASc score, mean (SD) 4.9 (1.3) 4.9 (1.3) 0.072
CHA2DS2-VASc score, % (n)
1 0 ,1% (2)
2 3% (65) 3% (326)
3 12% (309) 12% (1391)
4 24% (609) 26% (2980)
5 29% (736) 30% (3437)
6 20% (497) 19% (2150)
7 9% (222) 8% (941)
8 3% (67) 2% (285)
9 ,1% (9) ,1% (34)
Presenting characteristics
BMI, kg/m2 28 (25, 32) 28 (25, 32) 0.021
Systolic blood pressure, mmHg 130 (120, 140) 130 (120, 140) 0.99
Diastolic blood pressure, mmHg 80 (70, 85) 80 (70, 86) 0.021
Heart rate, b.p.m. 72 (63, 83) 76 (68, 86) ,0.0001
Creatinine clearance,a mL/min 68 (53, 88) 67 (52, 87) 0.039
Baseline comorbidities, % (n)
Prior stroke/TIA/SE 59% (1493) 54% (6207) ,0.0001
Prior stroke 36% (895) 34% (3940) 0.16
Prior TIA 27% (673) 21% (2395) ,0.0001
Significant valve disease 13% (328) 15% (1710) 0.022
PAD 6% (150) 6% (678) 0.85
Carotid occlusive disease 5% (124) 4% (459) 0.032
Hypertension 91% (2280) 91% (10 453) 0.79
Diabetes 37% (922) 41% (4684) 0.0003
Prior MI 19% (478) 17% (1954) 0.013
Heart failure
None 44% (1097) 36% (4159) ,0.0001
NYHA class I 8% (213) 8% (962)
NYHA class II 32% (805) 36% (4173)
NYHA class III/IV 16% (399) 19% (2251)
Chronic obstructive pulmonary disease 10% (263) 11% (1220) 0.87
Medications, % (n)
Prior VKA use 56% (1410) 64% (7431) ,0.0001
Prior chronic aspirin use 41% (1024) 35% (4090) ,0.0001
ACE inhibitor/ARB at baseline 73% (1829) 75% (8628) 0.042
b-Blocker at baseline 67% (1685) 64% (7447) 0.015
Continued
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with paroxysmal AF (prior stroke, TIA, or systemic embolism 59 vs.
54%, P, 0.0001). There were also differences in prior vitamin
K antagonist therapy (paroxysmal, 56 vs. 64% for persistent,
P, 0.0001) and prior chronic aspirin use (paroxysmal, 41 vs. 35%
for persistent, P, 0.0001).
Treatments during the follow-up
There was no imbalance in allocation to rivaroxaban or warfarin by
AF type; half of patients with paroxysmal and persistent AF were ran-
domized to rivaroxaban and half were randomized to warfarin.
During the follow-upofpatients allocated towarfarin, the TTRwas
similar between patients with paroxysmal and persistent AF (57 vs.
58%, P ¼ 0.94).
Use of aspirin during the follow-up was balanced between patients
with paroxysmal AF (21%) and those with persistent AF (20%). The
mean duration of aspirin use during the trial was 19 months in both,
and the mean dose was 90 mg for those with paroxysmal AF and
88 mg for those with persistent AF. Electrical cardioversion was
performed infrequently–144 in total. There were 58 (2.3%) in the
paroxysmal AF group and 86 (0.7%) in the persistent AF group.
Outcomes by atrial fibrillation type
Adjusted efficacy and safety outcomes, by AF type, are shown in
Table 2. Patients with paroxysmal AF had significantly lower rates
of stroke (adjusted HR: 0.78, 95% CI: 0.61–0.99, P ¼ 0.045), all-cause
mortality (adjusted HR: 0.79, 95% CI: 0.67–0.94, P ¼ 0.006), and
the composite of stroke or systemic embolism or death (adjusted
HR: 0.82, 95% CI: 0.71–0.94, P ¼ 0.005). Kaplan–Meier curves for
all-cause mortality, stratified by AF type, are shown in Figure 1.
The results were consistent throughout follow-up. Among
patients with paroxysmal AF, there was not any initial greater
excess of stroke or systemic embolism during the first month after
randomization that could have been attributed to a lower prevalence
of anticoagulation by VKA prior to randomization (Figure 1).
Lower hazards for patients with paroxysmal AF were consistent
across subgroups of the CHADS2 score, CHF diagnosis, presence
of chronic kidney disease, and history of stroke, for the composite
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Table 1 Continued
Paroxysmal AF (n5 2514) Persistent AF (n 5 11 548) P-value
Digitalis at baseline 24% (612) 42% (4808) ,0.0001
Diuretic at baseline 52% (1308) 61% (7076) ,0.0001
Antiarrhythmic drug at baseline 28% (714) 9% (1009) ,0.0001
TTR during follow-up, warfarin group, % 57 (44, 70) 58 (43, 71) 0.94
Continuous variables are shown as median (25th, 75th percentiles) unless otherwise noted.
ACE, angiotensin-convertingenzyme; AF, atrial fibrillation;ARB, angiotensin II receptorblocker;BMI, body mass index;MI, myocardial infarction;NYHA,NewYorkHeart Association;
PAD, peripheral artery disease; SD, standard deviation; SE, systemic embolism; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, vitamin K antagonist.
aCreatinine clearance calculated according to the Cockcroft–Gault equation.
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Table 2 Adjusted outcomes by type of atrial fibrillation
Outcomes Paroxysmal AF events/ 100
Pt-Yrs (total events)
Persistent AF events/ 100
Pt-Yrs (total events)
Paroxysmal vs. Persistent AF
adjusted HR (95% CI)
P-value
Efficacy outcomes
Stroke or SE 1.73 (85) 2.18 (480) 0.79 (0.63, 1.00) 0.048
All-cause death 3.52 (170) 4.78 (1029) 0.79 (0.67, 0.94) 0.0061
Stroke/SE/death 4.91 (233) 6.33 (1341) 0.82 (0.71, 0.94) 0.0047
Stroke or TIA 2.26 (110) 2.55 (560) 0.87 (0.71, 1.07) 0.19
Stroke 1.59 (78) 2.02 (446) 0.78 (0.61, 0.99) 0.045
TIA 0.67 (33) 0.56 (125) 1.13 (0.76, 1.67) 0.55
Safety outcomes
Major bleeding 3.31 (131) 3.55 (638) 0.97 (0.80, 1.17) 0.77
Efficacy end-point models were adjusted for the following: age, sex, body mass index, region, diabetes, prior stroke/TIA, vascular disease (myocardial infarction, peripheral artery
disease, carotid occlusive disease), congestive heart failure, hypertension, chronic obstructive pulmonary disease, diastolic blood pressure, creatinine clearance (calculated using
Cockcroft–Gault equation), heart rate, and abstinence from alcohol. Safety end-point models were adjusted for the following: age; sex; region; prior stroke/TIA; anaemia; prior
gastrointestinal bleed; chronic obstructive pulmonary disease; diastolic blood pressure; creatinine clearance (Cockcroft–Gault equation); platelets; albumin; and prior aspirin, vitamin
K antagonist, or thienopyridine use.
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TIA, transient ischaemic attack.
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end-point of stroke, systemic embolism, or death (Figure 2 and Sup-
plementary material online). There was a significant interaction
between AF type and (a) baseline rhythm (AF/atrial flutter vs.
sinus/other, Pinteraction ¼ 0.02), and (b) duration of AF diagnosis
(≤6 vs. .6 months, Pinteraction ¼ 0.02).
Outcomes by treatment assignment
Adjusted outcomes comparing rivaroxaban vs. warfarin-assigned
patients, stratified by AF type, are shown in Table 3. Corresponding
Kaplan–Meier curves of the primary end-point, for each of the four
groups, are shown in Figure 3. The relative treatment effects of rivarox-
abanvs.warfarinwereconsistent amongpatientswithpersistentAFand
paroxysmal AF. The number of stroke or systemic embolism events per
100patient-years in thosetreatedwithrivaroxabancomparedwithwar-
farinwasconsistent amongpatientswithparoxysmalAF(1.73%rivarox-
aban vs. 1.74% warfarin; adjusted HR: 1.00, 95% CI: 0.65–1.53) and
persistent AF (2.03 vs. 2.32%; adjusted HR: 0.88, 0.74–1.06,
Pinteraction¼ 0.60). The number of major bleeding events per 100
patient-years in those treated with rivaroxaban comparedwith warfarin
was consistent among patients with paroxysmal AF (3.43% rivaroxaban
vs. 3.19%warfarin; adjusted HR: 1.06, 95%CI: 0.75–1.49) and persistent
AF (3.61 vs. 3.49%; adjusted HR: 1.08, 0.92–1.26, Pinteraction¼ 0.94). All
tests of interaction between treatment assignment and AF type were
non-significant (Supplementary material online).
Discussion
Of the 14 264 patients randomized in the ROCKET-AF trial, a sizable
minority (18%) had paroxysmal AF at baseline. While patients with
persistent AF had some higher-risk features, compared with those
with paroxysmal AF, CHADS2 and CHA2DS2-VASc scores were
equivalent. After adjustment, thrombo-embolic and mortality out-
comes were consistently higher in patients with persistent AF, and
this association endured across high-risk subgroups (including
patients with prior stroke). There did not appear to be significant dif-
ferences in event rates between rivaroxaban and dose-adjusted war-
farin, across AF type.
Several prior cohorts have suggested no difference in outcomes
between patients with paroxysmal or persistent AF.14–16 However,
there are important distinctions of these studies. For example, in
the GISSI-AF post hoc analysis, a total of 1234 patients were studied,
and antithrombotic rates varied significantly between paroxysmal
and persistent (76 vs. 96%, P, 0.0001).14 Furthermore, mean
CHADS2 scores were dramatically lower compared with those in
ROCKET-AF (1.4 vs. 3.5). Similarly, a post hoc analysis of the
ACTIVE-W trial included patients with mean CHADS2 scores of
1.8–2.0; and while anticoagulation was not uniform by design,
therewere imbalances of the randomization scheme between parox-
ysmal and persistent AF patients (65% warfarin for paroxysmal vs.
85% for sustained AF, P, 0.0001).15 Lastly, in an analysis of 5533
Figure1 Unadjusted Kaplan–Meier event curves for all-cause mortality, by atrial fibrillation type at baseline. AF, atrial fibrillation, HR, hazard ratio;
CI, confidence interval.
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patients in the Euro Heart Survey, the authors identified dramatic dif-
ferences in the use of oral anticoagulation rates across several AF
types (ranging from 45 to 79%, P, 0.001), and highly dynamic subse-
quent management in these patients.16 Overall, these studies have
been significantly smaller than the present analysis (limiting their rela-
tive power); they frequently have lower risk and more heteroge-
neous populations (confounding comparisons); and most
importantly, none of these previously reported analyses included
consistently anticoagulated patients. The use of anticoagulation in
all patients likely had a significant impact on our findings, as historical
stroke/TIA events and anticoagulation use trended in opposite direc-
tions in paroxysmal AF patients in our cohort—they were less likely
to be previously exposed to anticoagulation but more likely to have
had prior stroke or TIA. Following uniform anticoagulation between
the groups (at randomization), our data demonstrate that patients
with persistent AF have worse outcomes, including thrombo-
embolic events and mortality.
Our findings extend observations from the Randomized Evalu-
ation of Long-Term Anticoagulation Therapy (RE-LY) and Apixaban
for Reduction in Strokeand Other Thrombo-embolic Events in Atrial
Fibrillation (ARISTOTLE) trials—patients enrolled in ROCKET-AF
had substantially higher CHADS2 scores than either of those trials
(mean 3.5 in ROCKET-AF vs. 2.1 in RE-LY and ARISTOTLE).17,18 In
our analysis, CHADS2 scores, CHA2DS2-VASc scores, and the
intensity of anticoagulation were all balanced between patients
with paroxysmal AF and those with persistent AF. Even in patients
at such high stroke risk, those with persistent AF still demonstrated
worse survival and higher risk of thrombo-embolic events. Further-
more, the effect on mortality appears to be a sustained phenomenon,
as event curves continue to separate out to 2.5 years of follow-up.
These data provide important insights into the risks associated
with more advanced forms of AF (i.e. those with persistent AF).
While the riskof strokehasbeenclear andremainspresent inpatients
with paroxysmal AF, it was not clear that outcomes are worse in
patients with persistent AF once stroke risk is treated with oral antic-
oagulation. Our data demonstrate that, in the setting of adequate
anticoagulation with either dose-adjusted warfarin or rivaroxaban,
persistent AF is associated with worse outcomes, and this finding
has important implications for overall AF treatment strategies
aimed at improving outcomes, including survival. It suggests that
the worse outcomes associated with advanced AF are unlikely to
be attributable to stroke risk alone, and may instead be related to
electromechanical or haemodynamic sequelae of the rhythm.
Notable prior studies have failed to demonstrate a substantive sur-
vival benefit to maintaining sinus rhythm; however, several concerns
have been raised with these data and they were not specific to
advanced AF.19– 21 Our analysis suggests there is an opportunity
for improving outcomes of patients with advanced AF, potentially
Figure2 Forest plot of the composite end-point of stroke, systemic embolism, or death for paroxysmal vs. persistent atrial fibrillation, stratified by
high-risk subgroups.All strata assessed at baseline. AF, atrial fibrillation; AFL, atrial flutter; CHF, congestive heart failure;CKD, chronic kidneydisease;
ECG, electrocardiogram; SE, systemic embolism.
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through disease-state modification. Rhythm control strategies such
as catheter ablation have been shown to slow progression, and
may provide an opportunity to improve clinical outcomes.22 There
is also emerging evidence supporting the use of such procedures in
patients with persistent AF.23 However, strategies such as risk
factor modification may also provide additional opportunities to
slow the disease progression.24
The lower risk of thrombo-embolic events and death in patients
with paroxysmal AF, compared with persistent AF, was particularly
pronounced in two subgroups—patients with the diagnosis of AF
.6 months prior to baseline, and those with rhythms other than
AF or atrial flutter on baseline ECG (Pinteraction ,0.05 for each).
While these remain hypothesis-generating results only, there are po-
tential explanations that deserve further study. The effect of AF dur-
ation may reflect diagnostic biases in patients with more recent
diagnoses, but both AF duration and ECG rhythm may also reflect
measures of burden of AF arrhythmia. Patients not in AF or atrial
flutter at baseline represent those with AF less likely to be captured
on any single ECG. Burden of AF has been an intensely studied topic,
and one of great debate. The Asymptomatic Atrial Fibrillation and
Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Re-
duction Atrial Pacing Trial (ASSERT) study suggested as little as 6 min
of AF increased stroke risk,25 and additional studies have demon-
strated some dose–response effect—that is, more AF portends
worse thrombo-embolic outcomes.26 Yet to date, neither AF type
nor AF burden is included in guideline-recommended risk stratifica-
tion for thrombo-embolism prophylaxis. This is likely due in part to
the difficulties of defining and measuring paroxysmal episodes of
AF, and additional studies of the implications of AF burden for treat-
ment decisions are required. However, patients with paroxysmal AF
remain at significant riskof stroke, relative to patients without AF, and
current evidence does not support withholding anticoagulation in
these patients. In contrast, our data suggest that the use of more ag-
gressive stroke prevention in patients with persistent AF, who are
otherwise at lower risk, deserves further study.
The treatment effects of rivaroxaban vs. adjusted-dose warfarin
were not different between patients with paroxysmal vs. persistent
AF. This finding is consistent with prior data, suggesting both
groups benefit from oral anticoagulation, particularly among patients
at high risk of stroke at baseline.15,27 However, those patients at the
highest risk of adverse outcome often derive the greatest benefit
from aggressive therapies; in our analysis, patients with persistent
AF were at substantially higher risk of thrombo-embolic events and
death. This may explain, in part, the variance in the hazards of rivar-
oxaban vs. dose-adjusted warfarin by AF type. However, none of
the differenceswas statistically significant andwiderconfidence inter-
vals indicate relatively under-powered assessments.
Limitations
The current study represents a post hoc analysis of the ROCKET-AF
trial, and is largely hypothesis generating. The classification of AF type
was made at the site level at baseline and there may be variation
(despite pre-specified definitions) or changes in AF type or burden
over time that are not captured. Additionally, patients with paroxys-
mal AF represented a minority of the overall cohort, and power to
detect differences in outcomes by treatment may be limited relative
to the overall trial population. This is particularly pronounced for
patients with low CHA2DS2-VASc scores—low numbers of patients
and events limits additional analyses at this low-risk end of the spec-
trum. Furthermore, although treatment assignment was balanced
and multivariable adjustment was performed, we cannot exclude sig-
nificant, unmeasured confounding in the comparison between
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Table 3 Adjusted outcomes of rivaroxaban vs. warfarin by atrial fibrillation type
Paroxysmal AF Persistent AF Interaction
P-value
Rivaroxaban
events/100
Pt-Yrs (total
events)
Warfarin
events/ 100
Pt-Yrs
(total
events)
Rivaroxaban
vs. Warfarin
adjusted HR
(95% CI)
Rivaroxaban
Events/100
Pt-Yrs (total
events)
Warfarin
events/100
Pt-Yrs
(total
events)
Rivaroxaban
vs. Warfarin
adjusted HR
(95% CI)
Efficacy outcomes
Stroke or SE 1.73 (42) 1.74 (43) 1.00 (0.65, 1.53) 2.03 (225) 2.32 (255) 0.88 (0.74, 1.06) 0.60
All-cause death 3.77 (90) 3.28 (80) 1.13 (0.83, 1.52) 4.53 (490) 5.02 (539) 0.91 (0.80, 1.02) 0.19
Stroke/SE/death 5.19 (122) 4.63 (111) 1.11 (0.86, 1.43) 6.05 (643) 6.62 (698) 0.92 (0.82, 1.02) 0.18
Stroke or TIA 2.19 (53) 2.32 (57) 0.95 (0.66, 1.39) 2.47 (272) 2.63 (288) 0.94 (0.80, 1.11) 0.96
Stroke 1.60 (39) 1.58 (39) 1.03 (0.66, 1.60) 1.91 (212) 2.13 (234) 0.91 (0.75, 1.09) 0.61
TIA 0.57 (14) 0.76 (19) 0.75 (0.37, 1.49) 0.57 (64) 0.54 (61) 1.05 (0.74, 1.49) 0.40
Safety outcomes
Major bleeding 3.43 (66) 3.19 (65) 1.06 (0.75, 1.49) 3.61 (323) 3.49 (315) 1.08 (0.92, 1.26) 0.94
Efficacy end-point models were adjusted for the following: age, sex, body mass index, region, diabetes, prior stroke/TIA, vascular disease (myocardial infarction, peripheral artery
disease, carotid occlusive disease), congestive heart failure, hypertension, chronic obstructive pulmonary disease, diastolic blood pressure, creatinine clearance (calculated using the
Cockcroft–Gault equation), heart rate, and abstinence from alcohol. Safety end-point models were adjusted for the following: age; sex; region; prior stroke/TIA; anaemia; prior
gastrointestinal bleed; chronic obstructive pulmonary disease; diastolic blood pressure; creatinine clearance (Cockcroft–Gault equation); platelets; albumin; and prior aspirin, vitamin
K antagonist, or thienopyridine use.
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TIA, transient ischaemic attack.
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paroxysmal and persistent AF patients. Lastly, generalizability may be
limited: these data are derived from a randomized trial population;
few warfarin-treated patients had TTR .70%; and patients were
generally of high stroke risk.
Conclusions
Among patients at a high risk of stroke who are receiving anticoagula-
tion, those with persistent AF have a higher risk of thrombo-embolic
events and death compared with those with paroxysmal AF. This
effect is consistent across subgroups, and outcomes in both AF
types did not differ between patients treated with rivaroxaban vs.
dose-adjusted warfarin. These data have important implications for
the management of patients with advanced AF, and additional data
are needed regarding the potential benefit of therapies aimed at
reducing AF persistence.
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Supplementary material is available at European Heart Journal online.
Funding
This work and the ROCKET-AF trial were supported by Janssen
Research & Development LLC, Raritan, NJ; and Bayer HealthCare AG,
Leverkusen, Germany. B.A.S. was funded by the National Institutes
of Health (NIH T-32 training grant #5 T32 HL 7101-38). Funding to
pay the Open Access publication charges for this article was provided
by Janssen Research & Development LLC, Raritan, NJ; and Bayer
HealthCare AG, Leverkusen, Germany.
Conflict of interest: B.A.S., A.S.H., and Y.L.: none. N.R.P.: honoraria
from Johnson & Johnson and Bayer HealthCare for serving on the execu-
tive committee of the ROCKET-AF trial; consulting fees from Ortho
McNeil Janssen, and Bayer HealthCare; and advisory board fees from
Genzyme. G.B.: honoraria from Johnson & Johnson and Bayer; and advis-
ory board fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer,
and Sanofi-Aventis. G.J.H.: honoraria for serving on executive commit-
tees for Johnson & Johnson and Bayer. R.C.B.: consulting fees/honoraria
and/or research grant support from Johnson & Johnson, Regado, Boeh-
ringer Ingelheim, AstraZeneca, Daiichi-Sankyo. D.E.S.: supported, in
part, by the Eliot B. and Edith C. Shoolman fund of the Massachusetts
General Hospital (Boston, MA, USA); has served as a consultant and/or
member of a scientific advisory board for Bayer, Boehringer Ingelheim,
Bristol-Myers Squibb, Daiichi-Sankyo, Johnson & Johnson, and Pfizer;
has an institutional research support contract with Johnson & Johnson;
served as an unpaid ROCKET-AF executive committee member. J.L.H.:
consulting fees/honoraria and/or research grant support from AstraZe-
neca, Bayer AG HealthCare, Boehringer Ingelheim, Daiichi-Sankyo,
Johnson & Johnson, Pfizer, Sanofi-Aventis, Biotronik, Inc. Hacke: consult-
ing fees/honoraria and/or research grant support from Bayer, Johnson &
Johnson, and Boehringer Ingelheim. C.C.N.: employee of Janssen Re-
search & Development LLC. S.D.B.: employee of Bayer. K.W.M: consult-
ing fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Forest, Johnson
Figure 3 Unadjusted Kaplan–Meier event curves for stroke or systemic embolism, by atrial fibrillation type and treatment assignment. AF, atrial
fibrillation; HR, hazard ratio, CI, confidence interval.
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation 295
& Johnson, WebMD. K.A.A.F.: grant funding and honoraria from Bayer
and Johnson & Johnson. R.M.C.: available at https://www.dcri.org/
about-us/conflict-of-interest/Califf-COI_2–3–2014.pdf. J.P.P.: research
grants from ARCA Pharmaceuticals, Janssen, GE Healthcare, and
ResMed and provides consulting to Forest Laboratories, Janssen, Med-
tronic, and Spectranetics.
References
1. Suzuki T, Yamazaki T, Ogawa S, Nagai R, Yamashita T. Echocardiographic predictors
of frequencyof paroxysmal atrial fibrillation (AF) and its progression to persistent AF
in hypertensive patients with paroxysmal AF: Results from the Japanese Rhythm
Management Trial II for Atrial Fibrillation (J-RHYTHM II Study). Heart Rhythm
2011;8:1831–1836.
2. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O’Neill J, Silva-Cardoso J,
ZharinovO, Gamra H,Alam S, Ponikowski P, Lewalter T, RosenqvistM, Steg PG. Dis-
tribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation
in routine clinical practice: insight from the real-life global survey evaluating patients
with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:
632–639.
3. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L,
Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C,
Liu CY, Berry SM, Berry DA, ThermoCool AFTI. Comparison of antiarrhythmic
drug therapy and radiofrequency catheter ablation in patients with paroxysmal
atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333–340.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A,
Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M,
Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the
management of atrial fibrillation: the Task Force for the Management of Atrial Fibril-
lation of the European Society of Cardiology (ESC).EurHeart J 2010;31:2369–2429.
5. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ.
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6
Suppl):546S–592S.
6. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GY,
Crijns HJ. Should we abandon the common practice of withholding oral anticoagula-
tion in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915–922.
7. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa in-
hibition compared with vitamin K antagonism for prevention of strokeand Embolism
Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J
2010;159:340–347 e1.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation
of clinical classification schemes for predicting stroke: results from the National
Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.
9. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR,
Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC,
Nessel CC, FoxKA, Califf RM. Renal dysfunction as a predictor of stroke and system-
ic embolism in patients with nonvalvular atrial fibrillation: validation of the
R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct
factor Xa inhibition Compared with vitamin K antagonism for prevention of
stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and
Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224–232.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD,
Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N
Engl J Med 2011;365:883–891.
11. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC,
Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL,
Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM, Investigators
RA. Factors Associated with Major Bleeding Events: Insights from the ROCKET
AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with
vitamin K antagonism forpreventionof strokeandembolism trial in atrial fibrillation).
J Am Coll Cardiol 2014;63:891–900.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance fromserum creatinine.
Nephron 1976;16:31–41.
13. Rubin DB. Inference and missing data. Biometrika 1976;63:581–592.
14. Disertori M, Franzosi MG, Barlera S, Cosmi F, Quintarelli S, Favero C, Cappellini G,
Fabbri G, Maggioni AP, Staszewsky L, Moroni LA, Latini R. Thromboembolic event
rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
BMC Cardiovasc Disord 2013;13:28.
15. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, Connolly SJ. Inci-
dence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking
oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
J Am Coll Cardiol 2007;50:2156–2161.
16. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM,
Widdershoven JW, Baur LH, Levy S, Crijns HJ. Prognosis, disease progression, and
treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart
Survey on atrial fibrillation. Eur Heart J 2008;29:1181–1189.
17. Flaker G, Ezekowitz M, Yusuf S, Wallentin L, Noack H, Brueckmann M, Reilly P,
Hohnloser SH, Connolly S. Efficacy and safety of dabigatran compared to warfarin
in patients with paroxysmal, persistent, and permanent atrial fibrillation: results
from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy)
study. J Am Coll Cardiol 2012;59:854–855.
18. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J,
Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of apix-
aban vs. warfarin by type and duration of atrial fibrillation: results from the ARIS-
TOTLE trial. Eur Heart J 2013;34:2464–2471.
19. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC,
Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control
and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:
1825–1833.
20. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL,
Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD,
Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG. Relationships
between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up In-
vestigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:
1509–1513.
21. Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, Rathod S,
Grant S, Thomas E, Wyse DG. Cardiovascular Outcomes in the AFFIRM Trial
(Atrial Fibrillation Follow-Up Investigation of Rhythm Management): an Assessment
of Individual Antiarrhythmic Drug Therapies Compared With Rate Control With
Propensity Score-Matched Analyses. J Am Coll Cardiol 2011;58:1975–1985.
22. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD,
Beresh H, Healey JS, Natale A. Radiofrequency Ablation vs Antiarrhythmic Drugs
as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). JAMA 2014;
311:692.
23. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A,
Arribas F, Fernandez-Lozano I, Bodegas A, Cobos A, Matia R, Perez-Villacastin J,
Guerra JM, Avila P, Lopez-Gil M, Castro V, Arana JI, Brugada J. Catheter ablation
vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, ran-
domized, controlled trial (SARA study). Eur Heart J 2014;35:501–507.
24. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, Ito Y, Kuroki K,
Machino T, Yamasaki H, Igarashi M, Sekiguchi Y, Sato A, Aonuma K. Concomitant ob-
structive sleep apnea increases the recurrenceof atrial fibrillation following radiofre-
quency catheter ablation of atrial fibrillation: clinical impact of continuous positive
airway pressure therapy. Heart Rhythm 2013;10:331–337.
25. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP,
Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES,
Hohnloser SH. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med
2012;366:120–129.
26. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C,
Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden
from implantable device diagnostics and stroke risk: the TRENDS study. Circ
Arrhythm Electrophysiol 2009;2:474–480.
27. Lip GY, Frison L, Grind M. Stroke event rates in anticoagulated patients with parox-
ysmal atrial fibrillation. J Intern Med 2008;264:50–61.
B.A. Steinberg et al.296
